FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors
Roche announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra (emicizumab-kxwh) for people with haemophilia A without factor…
Read More...
Read More...
